Case Report

Mucin-1 Gene Mutation and the Kidney: The Link between Autosomal Dominant Tubulointerstitial Kidney Disease and Focal and Segmental Glomerulosclerosis

H. Trimarchi, M. Paulero, T. Rengel, I. González-Hoyos, M. Forrester, F. Lombi, V. Pomeranz, R. Iriarte, and A. Iotti

1 Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
2 Pathology Service, Hospital Británico de Buenos Aires, Buenos Aires, Argentina

Correspondence should be addressed to H. Trimarchi; htrimarchi@hotmail.com

Received 14 April 2018; Revised 7 July 2018; Accepted 24 July 2018; Published 31 July 2018

1. Introduction

Focal and segmental glomerulosclerosis (FSGS) is classified into primary and secondary causes [1]. While the former is mainly due to still unidentified controversial circulating permeability factors and presents clinically with severe nephrotic syndrome and a grim prognosis, the latter may be due to numerous widely dissimilar etiologies with completely different pathophysiological mechanisms [1, 2]. In general, secondary causes of focal and segmental glomerulosclerosis present with lower levels of proteinuria and a slow decline in kidney function. Regardless of the cause, the main concern that encompasses focal and segmental glomerulosclerosis is the fact that it refers just to a morphological pattern of disease [1]. Finally, in general nephrologists tend to accept FSGS as a definitive diagnosis and mainly focus on the management of the clinical markers of kidney disease progression, as proteinuria and hypertension. Rarely do nephrologists search for the genetic causes that may cause FSGS and assume it to be of glomerular origin when evident causes of its secondary essence have been discarded, as HIV infection, ureterovesical reflux, obesity, pharmacological causes, hyperfiltration due to a reduction in the glomerular mass, cocaine abuse, and sickle cell disease, among others [1, 2]. Interestingly, the usually nonnephrotic range of proteinuria cannot differentiate between FSGS due to podocyte and slit diaphragms can occur from childbirth to adulthood with different clinical presentations, ranging from mild proteinuria and normal renal function to nephrotic syndrome and renal failure. However, this histopathological pattern can also be due to primary defects outside the glomerulus. The present report illustrates an adult case of secondary focal and segmental glomerulosclerosis with a dominant tubulointerstitial damage that led to the pursuit of its cause at the tubular level. In this patient with an undiagnosed family history of adult kidney disease, a genetic study unraveled a mutation in the mucin-1 gene and a final diagnosis of adult dominant tubular kidney disease-MUC1 was made.
The unexpected diagnosis of a mutation in the mucin gene (MUC-1) was made and remarks how a tubular derangement can cause secondary glomerular damage as glomerulosclerosis, underscoring that FSGS is a pattern of disease.

2. Case Presentation

A 56-year-old female was referred to the nephrologist due to apparently chronic kidney disease (CKD), diagnosed on a routine laboratory check-up. The patient was asymptomatic. Past medical record was contributory for three normal pregnancies. There was no background of alcohol intake, tobacco consumption, drug abuse, or medication exposure. There was a family history of CKD (Figure 1). Physical examination was unremarkable. Abnormal blood tests were as follows: Haematocrit 37%; haemoglobin 11.9 g/dL; bicarbonate 21 mEq/L; urea 78 mg/dL (normal value 20-50 mg/dL); serum creatinine 2 mg/dL; uric acid 6.4 mg/dL; creatinine clearance 42 ml/min; proteinuria 0.2 g/day; urinary sodium excretion 188 mEq/day; urine pH: 6; urinary protein 1015. Urinary sediment was unremarkable. HIV, HCV, and HBV were negative; C3, C4, and CH50 were within normal limits. ANA, p-ANCA, c-ANCA, antilomerular basement membrane antibody, and antiphospholipid antibodies were reported as negative. Renal sonogram disclosed two kidneys, normal in shape and size. A kidney biopsy was performed. Light microscopy disclosed 30 glomeruli: 6 completely obliterated, 8 presented peripheral sclerosis of the glomerular tuft with adhesions between parietal and visceral epithelial cells of Bowman’s capsule, and 6 depicted mild mesangial expansion (Figure 2).

Tubular atrophy and interstitial fibrosis were 30%. Blood vessels showed mild intimal sclerosis in arterioles. Immunofluorescence was negative. Electron microscopy: diffuse effacement of podocyte foot processes existed with microvillus transformation. Basal membrane was normal. Tubules were normal. Pathology report was as follows: focal and segmental glomerulosclerosis with moderate interstitial fibrosis and tubular atrophy. Patient was started on enalapril 5 mg twice a day and simvastatin 10 mg/day and on appropriate diet.

She was lost to follow-up. Sixteen months later the patient returned to the nephrologist due to asthenia, fatigue, and cramps. Blood pressure was 110/70 mmHg. Significant blood test results were as follows: Haematocrit 32%; haemoglobin 9.2 g/dL; bicarbonate 19 mEq/L; serum creatinine 9.5 mg/dL; serum phosphate 6.2 mg/dL; serum magnesium 2.2 mg/dL; urea 111 mg/dL; serum creatinine 3.78 mg/dL; uric acid 8.1 mg/dL; albumin 4.3 g/dL; creatinine clearance 21 ml/min; proteinuria 0.29 g/day; urinalysis was unremarkable. Urine pH was 7 and urinary density 1010. A renal magnetic resonance imaging was noncontributory. The patient was prescribed erythropoietin 2000 U every other day, enalapril 5 mg bid, calcium carbonate 2 g/day, sodium bicarbonate two tea spoons daily, and polystyrene calcium sulfonate. Six months later the patient was started on hemodialysis (creatinine clearance 12 mL/min). A genetic study disclosed the insertion of a cytosine nucleotide in the VNTR (Variable Number Tandem Repeats) region of the MUC-1 gene, consistent with a mutation of the mucin-1 gene previously reported [3]: cDNA NM_001204286.1, protein NP_001191215.1, SNaPshot. The diagnosis of ADTKD-MUC1 ( Autosomal Dominant Tubulointerstitial Kidney Disease-Mucin-1) was finally made. The laboratory results of the

Figure 1: Family tree.
Case Reports in Nephrology

3. Discussion

Our patient presented with a long lasting undiagnosed family history of chronic kidney disease (CKD) while some of her relatives had progressed to end-stage kidney disease as adults. As the clinical case was assumed as idiopathic chronic kidney disease, the kidney biopsy was considered mandatory. Moreover, the family background showed a slow but progressive trend of the disease that urged to obtain tissue promptly, as the benefits of performing a biopsy with diagnostic purposes is lower at advanced stages of CKD. In our opinion, as long-term proteinuria was mild, a primary glomerulopathy appeared unlikely. However, the pathology report informed that FSGS dominated the glomerular architecture. This was accompanied by moderate interstitial fibrosis, tubular atrophy, and interstitial inflammation, which were in accordance with the glomerular level of compromise and also with the clinical picture. Therefore, a secondary cause of FSGS was pursued. The concomitant occurrence of FSGS in a case of ADTKD, as previously reported [4], could be a histological pattern of injury secondary to the common end result of many chronic kidney conditions, in a nonspecific manner, and not as a direct cause of FSGS by the MUC-1 mutation.

The family tree suggested an autosomal dominant pattern of inheritance. In addition, the middle-age adult onset on chronic kidney insufficiency and end-stage kidney disease was an important aspect to take into consideration. Note-worthily, hypertension was not present either at stage 3 of CKD (at the time of diagnosis) or when the patient entered dialysis. Finally, both a low-grade proteinuria plus the medullar histologic findings were indicating a genetic tubular cause was to be ruled out. In this regard, an autosomal dominant tubulointerstitial kidney disease was taken into consideration [4–6].

Autosomal dominant tubulointerstitial kidney disease is a rare entity and is subclassified on a genetic basis that encompasses four mutations in the genes encoding uromodulin (UMOD), hepatocyte nuclear factor 1-β (HNF 1B), renin (REN), and mucin-1 (MUC-1) [4]. This novel and practical classification replaces cumbersome and confusing previous ones and suggests straightforward diagnostic criteria. Most of the clinical and histologic findings are nonspecific. As remarked in the KDIGO guidelines, there is usually a known familial history of kidney disease, and some members may have not been diagnosed properly due to death even before CKD symptoms arise, as it was the case in our patient’s father [4]. The average age of renal replacement therapy entrance is between 40 and 60 years, although this may depend on other variables as degree of penetrance of the mutation, hyperuricemia, and comorbidities [4–6]. Hypertension is typically absent in these subjects, while cysts are not predominant, although they can be more frequently encountered at advanced stages of these diseases, consequently not contributing to renal damage [4]. Due to their rarity, the prevalence and incidence of the different types of ADTKD remains unknown [4]. The main features although not exclusive of the four types are depicted in Table 1. Briefly, in ADTKD-UMOD, hyperuricemia and gout appear most frequently in adulthood and cysts are not frequent, but if present they tend to be cortical [4, 7, 8]. In ADTKD-REN, anemia (which resolves in puberty) and hypotension are present at childhood, while hyperuricemia and hyperkalemia are distinguishing features [4, 9]. In ADTKD-HNF1B, diabetes mellitus, pancreatic atrophy, and urogenital abnormalities are present, together with hypomagnesemia, hypokalemia, and liver function test abnormalities [10]. Finally, in ADTKD-MUC1, there are occasional cortical cysts and no other main characteristics [3, 4]. It may be presumed that the abnormal secreted mucin protein plugs in the distal tubule and causes an increase in the intraluminal pressure of the tubules, behaving as a postrenal cause of CKD. In this setting, this chronic situation impedes a normal clearance at the glomerular filtration barrier, leading to inflammation and glomerulosclerosis, as found in our patient (Figure 2).
mentioned above, the interstitial inflammation and tubular atrophy tend to dominate the biopsy picture. In the case of ADTKD-MUC1, distal tubular intracellular accumulation of the abnormal codified peptide named mucin fs can be identified for research purposes [4]. Histologically, FSGS has been described as a nonspecific finding in kidney biopsies of patients with ADTKD [4, 8, 11] (Table 1).

Mucins are highly molecular heavily glycosylated transmembrane proteins classified as secretary or membrane-bound. MUC1 is a membrane-bound mucin with a high expression throughout the distal nephron and is involved in the protection and lubrication of the distal tubular lumen [12, 13]. In addition, as a transmembrane protein it is involved in many intracellular functions, particularly in signal transduction [12, 13]. Although genetic testing for UMOD, REN, and HNF1B mutations is well established, MUC1 genetic testing remains challenging [11]. Finally, there is no specific therapy for this disease. In ADTKD, diuretics should be used with caution or avoided, as they may aggravate hyperuricemia and volume depletion [14]. Liberal water intake is recommended to compensate for possible urinary concentration defects. Nonsteroidal anti-inflammatory drugs should be avoided [4].

In conclusion, an initially diagnosed case of end-stage renal disease due to focal and segmental glomerulosclerosis with moderate tubulointerstitial compromise was later encountered to be secondary to a rare genetic mutation in mucin at the tubular level, known as ADTKD-MUC1.

Conflicts of Interest
No conflicts of interest related to the present study are declared by the authors.

References
[1] L. Zand, R. J. Glassock, A. S. de Vriese, S. Sithi, and F. C. Fervenza, “What are we missing in the clinical trials of Focal and Segmental Glomerulosclerosis?” *Nephrology Dialysis and Transplantation*, vol. 32, pp. 14–21, 2017.

[2] H. Trimarchi, “Primary focal and segmental glomerulosclerosis. Why are pieces of this puzzle still missing?” *European Medical Journal Nephrology*, vol. 3, no. 1, pp. 104–110, 2015.

[3] A. Kirby, A. Gnirke A, D. B. Jaffe et al., “Mutations causing medullary cystic kidney disease type I lie in a large VNTR in MUC1 missed by massively parallel sequencing.” *Nature Genetics*, vol. 45, no. 3, pp. 299–303, 2013.

[4] K. U. Eckardt, S. L. Alper, C. Antignac et al., “Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—A KDIGO consensus report,” *Kidney International*, vol. 88, pp. 676–683, 2015.

[5] A. J. Bleyer and S. Knoch, “Autosomal dominant tubulointerstitial kidney disease. of names and genes,” *Kidney International*, vol. 86, pp. 459–461, 2014.

[6] A. J. Bleyer, S. Hart, and S. Knoch, “Hereditary interstitial kidney disease,” *Seminars in Nephrology*, vol. 30, no. 4, pp. 366–373, 2010.

[7] F. Scolari, G. Caridi, L. Rampoldi et al., “Uromodulin storage diseases: clinical aspects and mechanisms,” *American Journal of Kidney Diseases*, vol. 44, no. 6, pp. 987–999, 2004.

[8] L. Rampoldi, F. Scolari, A. Morosolo et al., “The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease,” *Kidney International*, vol. 80, no. 4, pp. 338–347, 2011.

[9] M. Zivna, H. Hulkova, M. Matignon et al., “Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure,” *American Journal of Human Genetics*, vol. 85, no. 2, pp. 204–213, 2009.

[10] S. Faguier, S. Decramer, N. Chassaing et al., “Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood,” *Kidney International*, vol. 80, no. 7, pp. 768–776, 2011.

[11] X. M. Lens, J. F. Banet, P. Outeda, and V. Barrio-Lucía, “A novel pattern of mutation in uromodulin disorders: autosomal dominant medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy, and autosomal dominant glomerulocystic kidney disease,” *American Journal of Kidney Diseases*, vol. 46, no. 1, pp. 52–57, 2005.

[12] K. Mehla and P. K. Singh, “A novel master metabolic regulator,” *Biochemical Biophysical Acta*, vol. 1845, no. 2, pp. 126–135, 2014.

| UMOD | MUC1 | REN | HNF 1β |
|------|------|-----|--------|
| Clinical findings | Gout | Occasional cortical cysts | Hypotension | Diabetes mellitus |
| Age at presentation | adulthood | adulthood | childhood | Early childhood |
| Laboratory findings | Hyperuricemia | No characteristic findings | Hyperuricemia, Hyperkalemia | Hypomagnesemia, Hypokalemia |
| Pathology findings | Tubulointerstitial damage. Secondary FSGS | Tubulointerstitial damage. Secondary FSGS | Tubulointerstitial damage. Secondary FSGS | Elevated liver enzyme levels |

ADTKD, Adult dominant tubulointerstitial kidney disease; UMOD, uromodulin; MUC1, mucin-1; REN, renin; HNF 1β, Hepatocyte nuclear factor 1β; FSGS, focal and segmental glomerulosclerosis.
[13] P. J. Singh and M. A. Hollingsworth, "Cell surface-associated mucins in signal transduction," *Trends in Cell Biology*, vol. 16, no. 9, pp. 467–479, 2006.

[14] L. Labriola, E. Olinger, H. Belge et al., "Paradoxical response to furosemide in uromodulin-associated kidney disease," *Nephrology Dialysis and Transplantation*, vol. 30, no. 2, pp. 330–335, 2015.